Modulation of electrostatic interactions to reveal a reaction network unifying the aggregation behaviour of the Aβ42 peptide and its variants†

Georg Meisl, Xiaoting Yang, Christopher M. Dobson,* Sara Linse* and Tuomas P. J. Knowles†

The aggregation of the amyloid β peptide (Aβ42), which is linked to Alzheimer’s disease, can be altered significantly by modulations of the peptide’s intermolecular electrostatic interactions. Variations in sequence and solution conditions have been found to lead to highly variable aggregation behaviour. Here we modulate systematically the electrostatic interactions governing the aggregation kinetics by varying the ionic strength of the solution. We find that changes in the solution ionic strength induce a switch in the reaction pathway, altering the dominant mechanisms of aggregate multiplication. This strategy thereby allows us to continuously sample a large space of different reaction mechanisms and develop a minimal reaction network that unifies the experimental kinetics under a wide range of different conditions. More generally, this universal reaction network connects previously separate systems, such as charge mutants of the Aβ42 peptide, on a continuous mechanistic landscape, providing a unified picture of the aggregation mechanism of Aβ42.

Introduction

Most functional proteins have a net charge under normal physiological conditions, which helps confer solubility, and is governed by the protein sequence and structure, as well as the solution conditions such as pH, salt concentration and the concentration of other charged species. The interactions involving charged and polar groups modulate properties such as solubility, stability and reaction rates. In addition to their importance in the functional interactions of proteins, electrostatic interactions play a key role in the formation of aberrant protein aggregates. In particular, charged proteins with embedded hydrophobic segments can be highly aggregation-prone and their assembly into amyloid fibrils is associated with Alzheimer’s disease (the Aβ peptide), Parkinson’s disease (the protein α-synuclein) and a range of other debilitating human diseases. The aggregation kinetics of these proteins are strongly influenced by electrostatic interactions and therefore depend on solution conditions and the presence of species able to shield charges.

Recent years have seen a significant advance in the mechanistic understanding of the aggregation of disease-associated proteins under controlled conditions in vitro. The mechanistic effects of variations in solution conditions, however, have often not been characterised in detail and therefore only the part of the overall reaction network relevant under a given set of conditions has been investigated. The individual systems under different conditions are not linked together into a continuous mechanistic picture. A more complete reaction network will be particularly important in vivo where aggregation-prone proteins are found in the presence of a large number of other molecules, which modulate their interactions.

Here, we present a method of sampling a large region of the reaction network of an aggregating system by modulating electrostatic interactions. This approach provides a means of altering the relative importance of different processes contributing to the overall reaction network and thereby allows the sampling of a broad range of macroscopic behaviour that can be explained by a single reaction network. In the present work we investigate the aggregation kinetics of the 42-residue amyloid β peptide, Aβ42, at different peptide and salt concentrations under quiescent conditions. We develop a model that quantitatively accounts for the observed lag times, kinetic profiles and peptide concentration dependences over the range of ionic strengths studied and rationalizes the interplay of the individual microscopic rates and their dependence on the magnitude of the electrostatic screening.

Results and discussion

Monomeric Aβ42 has a net charge of between −3 and −4 at pH 8.0 where the C-terminus and Asp, Glu, Lys and Arg side chains...
are mostly ionized and the His side chains and the N-terminus may be partly protonated (Fig. 1a). Due to interactions of the charged groups, the specific value of the net charge is likely to change upon the alteration of conformation and close packing associated with assembly of the peptides into aggregates. The number of hydrophobic residues in the C-terminal segment of Aβ42 (Fig. 1a) gives this peptide a high aggregation propensity, despite the strong electrostatic repulsion between individual monomers.

In the present study the aggregation kinetics of Aβ42 at monomer concentrations ranging form 0.55 to 7 µM, and concentrations of up to 300 mM of added NaCl, in 4 mM phosphate buffer (giving an ionic strength of ≈ 12 mM in the absence of added NaCl), were recorded in triplicate repeats by monitoring thioflavin T (ThT) fluorescence (Fig. 1b), which is proportional to the total fibril mass (ESI Section 4.2†). Fibrillar structures of similar morphology were found to be formed at all monomer and salt concentrations as monitored by cryo electron microscopy (TEM) (Fig. 1c), however, fibrils are packed more densely at higher salt concentrations. The entire set of experiments was repeated with a fresh batch of purified peptide, at salt concentrations in the same range, yielding similar results, which are shown in the ESI, Section 1.3.† In order to analyse such a large body of kinetic data with a complex underlying mechanism we first set out to obtain general constraints on possible mechanisms by considering the qualitative features of the data.

Half times and scaling
The half time of the aggregation process is defined as the time by which half the final aggregate concentration has formed. In the first instance, the value of the half time is a guide to the aggregation propensity of a given system. For a charged peptide such as Aβ42, the aggregation propensity is expected to increase as the electrostatic repulsion between peptides becomes screened with increasing ionic strength. Indeed this accelerating effect of salt on the overall reaction rate was observed at all peptide concentrations examined in the present study, as is evident both from the kinetic curves in Fig. 1b and from the monotonic decrease in half times with increasing ionic strength, Fig. 2b. Similar results have been previously reported also for Aβ40 studied at a single peptide concentration.

To go beyond this very qualitative result and obtain mechanistic information, we consider the dependence of the half time $t_{1/2}$ on the monomer concentration, described by the scaling exponent $\gamma$ where $t_{1/2} \approx m_0^{\gamma}$ and $m_0$ is the monomer concentration at the beginning of an aggregation reaction. As outlined in Fig. 2a, the half time was determined for each kinetic curve at each monomer and salt concentration. The variation of the half time with varying salt concentration, at the same monomer concentration, shows the increase in aggregation propensity with increasing ionic strength, Fig. 2b. By contrast, from the variation of the half time with monomer concentration at the same salt concentration, the scaling exponent $\gamma$ can be extracted, Fig. 2c, giving one scaling exponent at each salt concentration. We observed that the average scaling exponent has a biphasic dependence on the ionic strength, Fig. 2d; at low ionic strengths the half time scales with $\gamma = -0.7$. As the ionic strength increases, the curvature in (c), indicative of a scaling exponent that depends on ionic strength is plotted in the bottom right panel (d). Note the variation of the double logarithmic plot of half time against ionic strength, Fig. 2d; at low monomer concentrations the half time scales with $\gamma = -0.7$. As the ionic strength increases, the curvature in (c), indicative of a scaling exponent that depends on ionic strength is plotted in the bottom right panel (d).
strength increases, the average scaling exponent reaches a minimum of \(-1.4\) at an ionic strength of around 32 mM and then increases again to \(-0.9\) at an ionic strength of 312 mM, the highest value used here. Therefore, as the ionic strength is increased, the half times decrease monotonically for all monomer concentrations, but the dependence of the aggregation rate on the monomer concentration, given by the magnitude of the scaling, is largest at intermediate ionic strengths of circa 30 mM.

In addition we observe that at some salt concentrations there are variations in the scaling exponent as the monomer concentration changes, resulting in curvature of the double logarithmic plots of half time versus monomer concentration: at low ionic strengths the scaling exponent increases significantly in magnitude (i.e. the monomer dependence of the reaction increases) as the monomer concentration is increased, for example from \(\gamma = -0.5\) to \(\gamma = -1.7\) at an ionic strength of 14.5 mM, Fig. 2c. The opposite curvature is evident at some higher ionic strengths where the scaling exponent decreases in magnitude (i.e. the monomer dependence of the reaction decreases, Fig. 5) as the monomer concentration increases.

In summary three distinct features emerge from this half time analysis: (1) the half times decrease with increasing ionic strength (as expected due to shielding of charge repulsion between peptides). (2) The half time scaling with monomer concentration is strongest at an ionic strength of approximately 30 mM and weaker at both lower and higher ionic strengths. (3) At some ionic strengths, the scaling exponent depends on the monomer concentration, i.e. there is curvature in double logarithmic plots of half time versus monomer concentration.

Development of an aggregation model

We next set out to develop a unifying model that reproduces these half time features and fits the time evolution of aggregate mass at all monomer and salt concentrations. Such a model will allow a determination of the underlying reaction network of the aggregation reaction and show how the dominant pathways through this network are shifted by changes in ionic strength. In order to derive a quantitative description of the kinetics of an aggregating system, we have used a master equation approach that aims to classify all the processes that contribute significantly to the aggregation reaction by their mathematical dependence on the monomer concentration, the overall fibril number and the fibril mass concentrations.

The elongation of the ends of growth competent fibril by the addition of monomers dominates the formation of fibril mass. In studies of the aggregation of other proteins, this elongation step has been found to saturate in our system, however, no saturation effects are observed (see ESI Fig. S9†) hence elongation is modelled as a single step reaction.

Whereas the production of fibril mass is dominated by a single process, three classes of processes are responsible for the formation of new aggregates and thereby new fibril ends (see Fig. 3): (1) processes that depend only on the monomer concentration, \(m(t)\), (e.g. homogeneous nucleation of monomers in solution) which form new aggregates with rate constant \(k_n\) and are of reaction order \(n_n\) in monomer concentration (referred to as primary nucleation). (2) Processes that depend on the monomer concentration and the fibril mass (e.g. heterogeneous nucleation on the fibril surface) produce new aggregates with rate constant \(k_4\) and are of order \(n_4\) in monomer (referred to as secondary nucleation). (3) Processes that depend only on the fibril mass (e.g. breakage of fibrils) and create new free ends with rate constant \(k_\text{f} \) (referred to as fragmentation). The latter two types of event are referred to as secondary processes as they involve the catalysis of the formation of new aggregates by existing aggregates.

Whilst primary nucleation and fragmentation may be assumed to be single step processes, secondary nucleation
consists of multiple steps in series, as we have established previously.29,30 The first step of secondary nucleation is a monomer-independent attachment step in which free monomers interact with the fibril surface and the second step is a monomer-independent detachment of a newly formed nucleus. The overall process can be dominated by either step, depending on the conditions, and the concentration at which the second step becomes rate limiting, i.e. the concentration at which all binding sites on the fibril are occupied, is determined by the constant $K_m$. By combining all these processes the full reaction network of aggregation is obtained, as displayed at the top of Fig. 3.

Experiments in which the aggregation was monitored following the addition of monomeric Aβ42 to preformed fibrils confirmed that the production of new aggregates in the present system is dominated by secondary processes, as shown in detail in the ESI, Section 3.1, Fig. S8.† Under these conditions fragmentation and secondary nucleation produce significantly more new aggregates than primary nucleation even at very low aggregate concentrations. In order to simplify the fitting and analysis we have considered two limits of this general reaction network, differing in their mechanism of the secondary process: in the first case both fragmentation and secondary nucleation, which act in parallel, may be significant, but we assume that there is no significant saturation of secondary nucleation (i.e. $K_m \gg m(t)^{n_2}$). We will refer to this case as the parallel limit and the corresponding scheme is shown in Fig. 3. The second case allows for saturation of secondary nucleation, but assumes that there is no significant contribution from fragmentation (i.e. $k_2 m(t)^{n_2} \gg k_1$). We will refer to this case as the saturation limit and the corresponding scheme is shown in Fig. 3c. The detailed solutions to the kinetics of these two limiting cases (see Methods) can be used to estimate the expected range of scaling exponents which are shown below each scheme in Fig. 3.

**Kinetic analysis**

We fitted the equations for both limits to the experimental data, obtained as described above, simultaneously for all monomer concentrations at each ionic strength (all results see ESI Section 1.3†). The parallel limit fits the data well at low and intermediate ionic strengths (see e.g. Fig. 4a), but becomes invalid at high ionic strengths (see ESI, Fig. S5†). The saturation limit fits the data at intermediate and high ionic strengths (Fig. 4c), but fails to reproduce the data at low ionic strengths (see Fig. 4b).

These results paint a clear picture of how the system goes through four distinct regimes, each defined by which mechanism dominates the production of new fibrils as the ionic strength increases (Fig. 5):

(I) At low ionic strengths (12–20 mM) the number of new growth competent ends produced by secondary nucleation and fragmentation is comparable (Fig. 5, 14.5 mM ionic strength): at low monomer concentrations fragmentation produces the largest number of new aggregates, resulting in a shallow dependence of the half time on monomer concentration, i.e. a scaling exponent of between $-0.5$ and $-1$. At high monomer concentrations secondary nucleation becomes the main source of new aggregates, resulting in a steeper dependence of the half time on monomer concentration with a scaling exponent of around $-1.5$. The average scaling exponent is circa $-1.0$.

(II) At intermediate ionic strengths (22–62 mM) fragmentation is negligible and secondary nucleation is not yet saturated: the monomer dependence of the half times is the same at all

![Global fits of the aggregation curves. (a) The top panel shows a global fit of the parallel limit, eqn (1), with three free parameters, to the all kinetic traces at 14.5 mM ionic strength. Shown below is a fit of just the half time behaviour for the same dataset. (b) The same data set as in (a) is fitted by the saturation limit, eqn (3). The fit of the network in the parallel limit (a) is significantly better than that of the saturation limit (b), the mean squared error in the parallel limit being half of that in the saturation limit. Note in particular how in the saturation limit we fail to reproduce the correct half times, as this limit cannot produce a decrease in scaling exponent with increasing monomer concentration. The saturation mechanism hence cannot explain the data at low ionic strengths. (c) By contrast to (b), a fit of the network in the saturation limit, eqn (3) with three free fitting parameters, to the data at 162 mM ionic strength shows good agreement with the experimental data. For clarity not all sampled concentrations are displayed in the plots of the full time courses; the fits were, however, performed on the entire dataset (see the ESI, Sections 1.1 and 1.2† for plots of the full dataset and an explanation of the deviation of the parallel limit fits at high monomer concentrations).](image-url)
monomer concentrations, and the points in the double logarithmic plots of half time versus peptide concentration in Fig. 5 at an ionic strength of 32 mM fall on a straight line. In this region the data follows a simple, single step secondary nucleation mechanism and therefore both the parallel and the saturation limit are equally valid. The average scaling exponent is close to its minimum value of −1.44.

(III) At ionic strengths beyond values where the average scaling exponent is at a minimum (circa 92 mM) secondary nucleation starts to saturate: at low monomer concentrations it is barely saturated, giving a scaling exponent of circa −1.5, whereas at high monomer concentrations saturation starts to become significant, giving a scaling exponent of circa −1.0. Some curvature is evident in the half time plots (92 mM ionic strength). At an ionic strength of 312 mM, secondary nucleation is fully saturated over the entire monomer range. At an ionic strength of 92 mM, secondary nucleation saturates as the monomer concentration increases, giving positive curvature. At an ionic strength of 312 mM, secondary nucleation is fully saturated over the entire monomer concentration range, again requiring only a single RDS.

Effect of ionic strength on individual microscopic processes

The global fitting of the aggregation curves above provides an explanation of the observed changes in half times and scaling exponents: the differential effect of a change in ionic strength on the rates of the individual processes in the aggregation reaction leads to shifts in the dominant mechanism of aggregate multiplication. In order to rationalize this difference in susceptibility to electrostatic shielding we consider the variation of each rate constant with ionic strength.

In the plots in Fig. 6a and b we show the logarithm of the various rate constant versus the square root of ionic strength (this latter value includes the contribution from the added salt as well as the buffer; in the absence of added salt the buffer alone (4 mM sodium phosphate, 40 μM EDTA, pH 8.0) results in an ionic strength of approximately 12 mM). In a simple Debye–Hückel (DH) model of the effect of ionic strength, these points would be expected to lie on a straight line. However, DH is accurate only at low ionic strengths, which are not accessible experimentally due to the need for a buffer during monomer isolation by size exclusion chromatography and to control the pH during the reaction and due to issues of irreproducibility which emerge in experiments with very low aggregation rates and long lag times as observed at low ionic strengths. Straight line fits up to an ionic strength of 100 mM are shown in Fig. 6, and although there is significant deviation from linearity, we can use the value of the slope to obtain an order of magnitude estimate of the charge of the species involved, as a consistency check. The slope corresponds approximately to the product of the valency of the reacting ions. In case of the elongation rate, Fig. 6a, the slope is approximately 6, which is determined by the charge of a monomer and that of a free fibril end, consistent with a charge of −2 to −3 for each of these species. In the case of the combined elongation–nucleation rate constant, Fig. 6b, the slope is approximately 13. If we assume the contribution from
Fig. 6  Effect of electrostatic screening on the microscopic rates. (a) The elongation rate constant as measured in strongly seeded experiments (blue dots, experimental details in ESI Section 3.2†). (b) The product of the elongation rate constant and the primary nucleation rate constant at different ionic strengths, obtained from global fits of the specific equation valid at each ionic strength: green dots correspond to the parallel limit (three lowest ionic strengths), blue dots to the saturation limit (three highest ionic strengths); the green-blue dots are an average of the fits of the two limits in the region of intermediate ionic strength where both limits are equally valid (three intermediate ionic strengths). The blue lines are straight line fits up to 100 mM ionic strength. (c) The Michaelis constant, $K_M$ (blue dots), as obtained from global fits in the saturation limit at high ionic strengths (the region where the saturation limit is no longer valid is marked in red). As $\sqrt{K_M}$ gives the monomer concentration at which saturation effects become important, the region of monomer concentrations used in this study is marked in blue. Values of $K_M$ outside the sampled region are likely to be less accurate, as the variation of $K_M$ in this region will have very little effect on the aggregation kinetics. The corresponding points are shown as empty circles. The binding constant of monomers to fibrils was measured independently by SPR, and computed from the rates of adsorption and desorption (purple squares). (d) Ratio of the rates of production of new free ends from secondary nucleation and fragmentation at ionic strengths of 14.5 mM, 32 mM and 162 mM, at monomer concentrations of 2 $\mu$M (light blue) and 5 $\mu$M (dark blue). The ratio of fragmentation to secondary nucleation decreases both with increasing monomer concentration and increasing ionic strength. At ionic strengths of 162 mM and above, fragmentation is too slow to be measured. Error bars in all cases are obtained from fitting subsets of the data (see ESI Section 4.3†).

Elongation is again approximately 6 (this is additive), the contribution from nucleation to the slope is then 7, which again is consistent with a charge of $-2$ to $-3$ for the monomers reacting during primary nucleation (details see ESI Section 2.3†). Hence, although DH theory is inadequate to describe fully the behaviour of charged macromolecules at the high ionic strengths studied here, the estimates it yields for the charges of the reacting species are in good agreement with the peptide sequence (Fig. 1a) and hence consistent with an electrostatic effect.

Elongation rate constant. The fitting of data obtained in the absence of the addition of any preformed fibrils yields the rate constants in the form of products, $k, k_2$, $k_4, k_5$, and $k, k_4$, as the kinetics of such unseeded aggregation reactions depend only on these combinations rather than on the rate constants individually. An estimate for the elongation rate constant, $k_4$, can be obtained by performing experiments under strongly seeded conditions and measuring the initial increase in aggregate mass, which is determined only by the elongation of the seeds and not affected by nucleation processes. In order then to extract the value for the elongation rate constant, the number of seed fibrils needs to be determined. To this end, in the present study several TEM measurements were performed in order to obtain an estimate of the average length of the fibrils. The fibril lengths obtained in this way are only approximate and hence the elongation rates are estimated to be accurate only to within an order of magnitude; the absolute value of $k_4$ should therefore be interpreted with caution. Its relative variation with ionic strength does, however, not suffer from such inaccuracies (details see ESI Section 3.2†). The elongation rate is found to increase by approximately one order of magnitude as the ionic strength is varied between 12 and 52 mM, Fig. 6a.

Nucleation rate constants. The product of the primary nucleation rate constant and the elongation rate constant is the only quantity common to both limits and hence can be obtained for the entire range of salt concentrations from the global fits.
In the region of intermediate ionic strength (22 mM to 62 mM) the two limits yield the same mechanism (single step secondary nucleation without fragmentation) and hence in Fig. 6b, in the intermediate region, the average of the fits is shown (the values of the rate constants obtained from the two models differ slightly, because experimental variations affect the fits of the two models in a slightly different manner). The combined primary nucleation/elongation rate constant is found to increase by four orders of magnitude from the lowest to the highest ionic strength, which implies an increase of the primary nucleation rate constant by two to three orders of magnitude, and hence that primary nucleation is affected more strongly than elongation by the electrostatic shielding. This may be due to the fact that during primary nucleation a larger number of charged species come together to form the nucleus. The secondary nucleation rate constant shows an increase similar to that of the primary nucleation rate constant, whereas the fragmentation rate constant remains approximately constant (plots see ESI Fig. S5 and S6†). The increase in the ratio of nucleation rate to elongation rate is also in agreement with the decrease in fibril length observed in the TEM measurements (see ESI, Fig. S10†).

**Saturation concentration.** From fits of the saturation limit, the monomer concentration at which saturation of secondary nucleation occurs is found to decrease with increasing ionic strength. \(\sqrt{K_M}\) gives the monomer concentration at which saturation effects become important: if \(\sqrt{K_M}\) is above the region of monomer concentrations that are sampled in the experiment we expect the system to be unsaturated, if \(\sqrt{K_M}\) is within the region of monomer concentrations that are sampled we expect the system to start displaying saturation as the monomer concentration increases, and finally if the region of monomer concentrations that are sampled is above \(\sqrt{K_M}\) we expect the system to be fully saturated at all sampled monomer concentrations. The results show that \(\sqrt{K_M}\) decreases with increasing ionic strength, i.e. the system will begin to saturate at lower monomer concentrations the higher the ionic strength (Fig. 6c, blue dots). This observation can be rationalised by considering the fact that the monomer concentration dependent step in secondary nucleation involves an association reaction between negatively charged monomers and negatively charged fibrils, which will be slower at lower ionic strengths. By contrast the monomer-independent detachment step is dominated by short range interactions and rearrangements, which is therefore likely to be less affected by the screening of electrostatic interactions. At high ionic strengths the monomer-dependent step becomes very fast, whereas the monomer-independent step proceeds at a rate similar to that at low ionic strength, and therefore it becomes rate limiting, leading to the observed saturation of secondary nucleation. To further investigate the origin of this observed behaviour we performed surface plasmon resonance (SPR) measurements to determine the equilibrium dissociation constant of monomers to fibrils, \(K_D\). In these experiments the dissociation constant was calculated from the association and dissociation rate constants which were determined by fitting (see ESI Section 2.4, Fig. S7†) rate equations to the increase and the decay of the SPR signal (Fig. 6c, purple squares). The dissociation constant obtained is approximately 1 \(\mu\)M and, given the larger errors on the SPR measurements, shows no significant variation with ionic strength. By comparison, previous studies of dissociation constants of charged macromolecules from SPR have measured ca. one order of magnitude decrease in \(K_D\) upon an increase from low to physiological salt concentrations.35

Note that the saturation concentration \(\sqrt{K_M}\) in addition to being dependent on the strength of the adsorption to the fibrils, also depends on the interaction between the monomers forming the nucleus. Therefore it is not directly comparable in magnitude to the equilibrium dissociation constant, \(K_D\), obtained from SPR. The fact that the variation of \(\sqrt{K_M}\) is not reflected in the values of the binding constant from SPR would suggest that the ionic strength dependence largely originates in the contributions of monomer–monomer interactions to \(\sqrt{K_M}\). However, due to the differences of the two systems, (the fibrils are surface bound in SPR experiments, rather than in solution as in the aggregation experiments and effects from partial charges of the dextran may perturb SPR data at low ionic strength) and the large errors associated with the SPR measurements, further experiments will be required to verify this finding.

**Dominant secondary process.** Which of the two secondary processes dominates the multiplication of aggregates is determined by both the ionic strength and the monomer concentration. To illustrate this point, we have considered the relative number of new aggregates produced by secondary nucleation and by fragmentation, at three different ionic strengths and two monomer concentrations (Fig. 6d). At an ionic strength of 14.5 mM and low monomer concentrations, the ratio of fragmentation to secondary nucleation is close to 1, and the two processes both contribute to the kinetics. At higher monomer concentrations, secondary nucleation is faster, as its rate increases with monomer concentration whereas fragmentation is independent of the monomer concentration. As the ionic strength is increased to 32 mM, the rate of secondary nucleation increases significantly, whereas the fragmentation rate does not match this increase, making the contribution of fragmentation to the aggregation reaction insignificant even at low monomer concentrations. At even higher ionic strengths, the fragmentation rate is too low to be detected in the fitting.

Although the aggregation behaviour of Aβ42 is evidently complex over the entire salt and monomer concentration ranges, it can be rationalised completely by considering the effect of ionic strength in terms of an increase of the association rates of the various microscopic processes. The more charged species associate in a given process, the more it is a surface phenomenon. These different variants of Aβ interact in a different way to the association of fibrils, therefore the question arises if the reaction network obtained here offers a way to
Table 1 Reaction network to unify variants of Aβ. The kinetics of previously published Aβ aggregation data are compared to the mechanisms found in the present work at different ionic strengths. Unless otherwise stated these experiments were performed under quiescent conditions, at pH 8.0 and an ionic strength of approximately 40 mM. Aβ42-ext 15 refers to Aβ42 that has been extended by 15 residues at N-terminus.36 Check the references for further details.

| System | Scaling | Path through reaction network | Analogous to Aβ42 (pH 8) at | Proposed rationalisation (behaviour relative to Aβ42 (ref. 31)) |
|--------|--------|-----------------------------|----------------------------|---------------------------------------------------------------|
| Aβ40 (ref. 29) | –1.2 to –0.5 | Saturating 2° nuc | Medium to high ionic strength | Decreased detachment rate of 2° nuclei |
| Aβ42 (shaking)31 | –0.6 | Fragmentation | Low ionic strength, low monomer | Increased fragmentation from shear forces |
| Aβ42-A2V37 | –1.5 to –0.5 | Saturating 2° nuc | Medium to high ionic strength | Increased 2° nucleation, (more hydrophobic) |
| Aβ42 (pH 7.4)37 | –1.5 to –0.5 | Saturating 2° nuc | Medium to high ionic strength | Increased 2° nucleation, (less charged) |
| Aβ42-ext 15 (ref. 36) Aβ42-E22G38 | Approx –1.3 to –0.5 | Non-saturated 2° nuc | Medium ionic strength | Unchanged from Aβ42 |
| | | Fully saturated 2° nuc | High ionic strength | Increased 2° nucleation, (less charged) |

connect these different variants in a single mechanistic picture. Indeed many variants of Aβ under a range of conditions aggregate via a pathway that is part of this general reaction network, summarised in Table 1. Generally we find that effects that increase the fibril coverage during secondary nucleation or increase the rate of attachment of monomers to fibrils relative to the detachment of newly formed nuclei lead to an aggregation mechanism that is dominated by a saturating, or saturated, secondary nucleation mechanism, a process often associated with toxicity.9–10 This is the case for the aggregation of Aβ42 at a slightly lower pH of 7.4,37 as well as the aggregation of the mutants A2V37 and E22G.38 The reasons for increased fibril coverage in these cases are believed to be a decreased electrostatic repulsion as more residues become protonated at lower pH, a higher hydrophobicity and hence stronger binding of monomers to fibrils for A2V, and again a lowering of the electrostatic repulsion due to the loss of a charged sidegroup for E22G. This behaviour is analogous to the increased fibril affinity of monomers we observed here at high ionic strengths. We previously found that the other major variant of the Aβ peptide, Aβ40, aggregates via a saturating secondary nucleation mechanism, however the overall rates are lower than in the case of Aβ42, possibly due to a decreased nucleus formation/detachment step, rather than an increased binding, during secondary nucleation. By contrast, N-terminally extended variants of Aβ42 aggregate via an unsaturated secondary nucleation mechanism, which is likely to be due to the reduced number of reactive encounters of fibrils and monomers and therefore a saturation of the fibril surface is not reached at the studied monomer concentrations.36 Finally our extended reaction network also connects the aggregation behaviour of Aβ42 under strong agitation,31 with the behaviour under quiescent conditions: the shear forces induced by shaking significantly increase the rate of fragmentation and the mechanism shifts to one dominated by fragmentation. An analogous effect can be produced by significantly lowering the rate of the other nucleation processes, as we have observed here at low salt concentrations, allowing fragmentation to become kinetically visible.

Conclusion

In this work we have shown that electrostatic screening can be used to modulate the relative importance of different microscopic processes and thereby alter the specific pathway that dominates the conversion of soluble peptides to their amyloid forms. This approach has allowed us to tackle a complex reaction network and to establish a mechanistic framework that accounts fully for the aggregation behaviour of Aβ42 over a wide range of solution conditions and monomer concentrations. As the individual rate constants are altered by the increasing electrostatic shielding, modifying the interplay and competition of the different microscopic processes, four distinct types of macroscopic behaviour emerge. The rate of fragmentation is found to be largely unaffected by variations in ionic strength and only contributes notably at low ionic strengths and monomer concentrations. By contrast, the rate constants for primary and secondary nucleation each increase by approximately two orders of magnitude and the rate constant of elongation increases by circa one order of magnitude, upon increasing the ionic strength from 12 mM to 312 mM.

These findings show that the modulation of electrostatic interactions has profound mechanistic effects beyond a simple overall increase in aggregation propensity, and due to its differential effect on the individual rates it represents a means to sample an extended reaction network. The general reaction network we obtained through this sampling of a large proportion of the space of possible aggregation mechanisms serves as a unified framework for describing the aggregation behaviour of the variants of the Aβ peptide. The analysis detailed here, therefore, serves as a basis for interpreting how changes in solution conditions or peptide sequence shift the dominant pathways in the reaction network. It provides a continuum of mechanisms connecting the varied behaviour of different systems. In particular it allows the determination of the extent to which any alterations of the peptide sequence or the solution conditions correlate with those produced by altered
electrostatic screening, thereby providing key insights into the physical origin of any observed mechanistic differences.

Materials and methods

**Aβ42 expression and purification**

Aβ(M1-42), of sequence shown in Fig. 1, here referred to as Aβ42, was expressed in *E. coli* from a synthetic gene and purified in batch format using ion exchange (see ESI, Fig. S10†) and size exclusion steps as described in Walsh et al. This results in highly pure monomeric peptide, which was divided in identical aliquots and stored as lyophilized peptide powder.

**Samples for aggregation kinetics**

Monomeric Aβ42 was isolated twice by gel filtration of aliquots of purified peptides just prior to preparing each of the experiments, to remove any traces of aggregates formed during freezing and thawing and to exchange the buffer. The peptide powder was dissolved in 6 M GuHCl at pH 8.0 and the monomer peak was collected in low-bind Eppendorf tubes (Axygen) on ice and the concentration was determined by absorbance at 280 nm using an extinction coefficient of 1440 l mol⁻¹ cm⁻¹. Gel filtration was performed in 20 mM sodium phosphate, 0.2 mM EDTA, pH 8 at high enough concentrations that the isolated monomeric peptide could be diluted 5-fold with water or NaCl and still contain monomer concentrations of up to 5–7 μM. The final solutions used in the aggregation assays contained 4 mM sodium phosphate buffer, pH 8.0, with 40 μM EDTA, 6 μM ThT and NaCl in the range between 0 to 300 mM. The monomer concentration was varied between 0.5 and 7 μM and the ThT concentration (6 μM) was chosen to be in the range that has been shown to provide a response that is linearly dependent on the total aggregate mass. Here, this linearity was found to hold at all salt concentrations. At 0–10 mM NaCl the fluorescence intensity is higher the lower the salt concentration, but the response still varies linearly with monomer concentration for each salt concentration. All solutions used in gel filtration and in the preparation of sample series were extensively degassed. The aggregation kinetics were studied at 37 °C under quiescent condition by recording the ThT fluorescence intensity as a function of time using a plate reader (Fluostar Omega or Optima, BMG Labtech, Offenberg, Germany). The fluorescence was recorded in half-area 96-well PEG-coated black polystyrene plates with clear bottoms (Corning 3881, Massachusetts, USA) measuring from below with a 440 nm excitation filter and a 480 nm emission filter.

**Surface plasmon resonance (SPR) assays**

Aβ42 monomer samples were prepared as described above for aggregation kinetics. Monomeric samples were loaded in a 96-well PEG-coated polystyrene plate (Corning 3881, USA) and 6 μM ThT was added to one of the wells as a fluorescence control. Fibrils were formed at 37 °C in 20 mM sodium phosphate buffer with 0.2 mM EDTA at pH 8. Fluorescence intensity was monitored as described above for aggregation kinetics and the reaction was terminated when the ThT signal of the control well reached the plateau. To immobilize the Aβ42 fibrils covalently on the surface of a CM3 sensor chip (GE Healthcare Life Sciences, USA) through amine coupling, 100 μl of a 1:1 fresh mixture of 0.05 M NHS and 0.2 M EDC was injected and flowed through the channels to active the chip surface. The Aβ42 fibril sample was then flown through three channels and one channel was left as a negative control. Ethanolamine was used afterwards to block the remaining active site on the chip. Aβ42 monomer samples were diluted 5-fold with water and added to a highly concentrated NaCl solution to reach final concentrations of 7 μM and 3 μM Aβ42, 4 mM sodium phosphate, 40 μM EDTA, and 2.5 mM, 12 mM and 150 mM NaCl, at pH 8.0. The Aβ42 binding test was performed at two monomer concentrations, 7 μM and 3 μM at three ionic strengths, 14.5 mM, 24 mM and 162 mM. The fibril covered surface was equilibrated in buffers of the same ionic strength accordingly before the measurement. The binding test was performed at 37 °C, on Biacore 3000 instrument (GE Healthcare Life Sciences, USA). 40 μl sample was injected at each measurement and the dissociation process was monitored at a flow rate of 30 μl min⁻¹. By fitting the dissociation curves to a sum of a linear and exponential function, the maximum coverage was determined (see ESI Section 2.4†).

**Cryogenic transmission electron microscopy (TEM)**

Aβ42 monomers were purified as described above for aggregation kinetics. The sample was diluted with water and highly concentrated NaCl solution was added to give samples with 10 μM Aβ42 monomer in sodium phosphate buffer with ionic strengths of 29 mM, 57 mM and 150 mM. The samples were loaded in a 96-well PEG-coated polystyrene plate (Corning 3881, USA) and ThT was added to one well at each ionic strength as the fluorescence control. Fibrils were formed in the same way as described above for SPR and 5 μl sample at each ionic strength was loaded as a liquid film on a lacey carbon filmed cooper grid. A layer of sample less than 300 nm thick was produced on the grid by blotting the extra liquid away at the back of the grid using a filter paper, followed by flash freezing the grid in liquid ethane and stored in liquid nitrogen. The grid preparation was carried out in a controlled environment vitrification system to ensure the stable temperature and humidity in order to maintain the original states of the sample. Images were recorded using a 120 kV electron microscope (Philips CM120 BioTWIN Cryo) with a CCD camera.

**Theoretical model**

The time evolution of aggregate mass, $M(t)$, in the parallel limit is given by:

$$M(t) = m_0 + \exp \left[ -\frac{k_s (4ck_s \cosh(kt) + 4P_0k_c^2 \sinh(kt))}{2k^4} \right] \times \left( m_0 - m_{tot} \right) e^{\frac{2k^4}{\bar{c}^2}}$$

where
where \( m_{\text{tot}} \) is the total protein concentration, \( M_0, P_0, m_0 \) are the initial mass concentration of fibrils, number concentration of fibrils and monomer concentration, respectively. \( k_1, k_2, k_n \) and \( k_3 \) are the rate constants of elongation, fragmentation, primary nucleation and secondary nucleation.

In the saturation limit we obtain:

\[
\frac{M}{M_s} = 1 - \left(1 - \frac{M_0}{M_s}\right)^{\frac{1}{\kappa}}\left(\frac{B_s + C_s e^{\frac{g}{k_s}}}{B_s + C_s}\right)^{\frac{k}{k_s}}
\]

where the definitions of the parameters are

\[
\kappa = \sqrt{2m_0 k - m_0^2 k_2 / K_M}
\]

\[
\lambda = \sqrt{2k_1 m_0 k_2}
\]

\[
C_s = \frac{k_2 P_0}{\kappa} + \frac{k_1 M_0 + \lambda^2}{2mk_1 k_2}
\]

\[
k_s = 2k + P_s
\]

\[
\overline{k_s} = \sqrt{k_s^2 - 2C_s k_s^2}
\]

\[
B_s = \frac{k_s + \overline{k_s}}{2}
\]

Again \( m_0 \) is the initial monomer concentration, \( P_0, M_0 \) and \( P_s, M_s \) are the aggregate number and mass concentrations at the beginning of the reaction and at equilibrium, i.e. after completion of the aggregation reaction. The details of the derivation of these equations can be found in the ESI Section 2.1.† A discussion about how these models relate to models explicitly including oligomers can be found in ESI Section 2.3.†

Note that for unseeded experiments (i.e. experiments starting from monomer alone, without preformed fibrils) the two limiting cases only involve three free parameters each \((k,k_2, k_2,n\) and \(k_1,k_2, k_1,n \) in the parallel limit and \(k,k_2, k_2,n \) in the saturation limit), which were found to be sufficient in the present study to produce high quality global fits to all monomer concentrations at any given salt concentration. In the parallel limit, the scaling exponents are given by:

\[
\gamma_{\text{comp}} = \frac{d \log (t_{1/2})}{d \log (m(0))} = -\frac{1}{2} \left(\frac{n_s}{1 + K/m(0)^n} + 1\right)
\]

where \( K = k_1/k_2 \). This expression interpolates between \( \gamma = -1/2 \) and \( \gamma = -(n_s + 1)/2 \) for the limits of low and high monomer concentration respectively, giving the negative curvature in the double logarithmic plots of the half time, as predicted from the qualitative argument used to derive the general constraints above.

In the saturation limit, the scaling exponent is given by:

\[
\gamma_{\text{sat}} = -\frac{1}{2} \left(\frac{n_s}{1 + m(0)^n/K_M} + 1\right)
\]

where \( K_M \) is the Michaelis constant. This expression interpolates between \( \gamma = -(n_s + 1)/2 \) and \( \gamma = -1/2 \) for the limits of low and high monomer concentration respectively, i.e. the reverse of the parallel limit.

**Fitting**

The data were normalised to give units of relative fibril mass concentration. The fits were performed using a basin-hopping algorithm29,42 on the AmyloFit fitting platform.21 Please see ESI Section 4.4† and Meisl et al.24 and references therein for details. There were three global fitting parameters (i.e. one value of each parameter for all monomer concentrations) at each salt concentration: \( k_1,k_2,k_n \) and \( k_1,k_2,k_M \) in the parallel limit, and \( k_1,k_2,k_3 \), and \( K_M \) for saturation limit. The reaction orders of primary and secondary nucleation, \( n_1 \) and \( n_s \), were both fixed to 2, in line with the values found for Aβ42 in previous work.23 The effect of fitting the reaction orders, which were set to the value previously established at a single salt concentration,24 is discussed in the ESI Section 1.2.†

**Acknowledgements**

We thank Gunnel Karlsson, Lund University, for excellent help with cryo-EM. The research leading to these results has received funding from the European Research Council under the European Union’s Seventh Framework Programme (FP7/2007-2013) through the ERC grant PhysProt (agreement no 337969) (SL, TPJK), Sidney Sussex College Cambridge (GM), the Frances and Augusta Newman Foundation (TPJK), the Biotechnology and Biological Science Research Council (TPJK), the Swedish research Council (SL), and China Scholarship Council (XY).

**References**

1. M. S. Lawrence, K. J. Phillips and D. R. Liu, *J. Am. Chem. Soc.*, 2007, 129, 10110–10112.
2. M. Kurnik, L. Hedberg, J. Danielsson and M. Oliveberg, *Proc. Natl. Acad. Sci. U. S. A.*, 2012, 109, 5705–5710.
3. D. N. Marti and H. R. Bosshard, *Biochemistry*, 2004, 43, 12436–12447.
4. S. Lindman, S. Linse, F. A. A. Mulder and I. Andre, *Biochemistry*, 2006, 45, 13993–14002.
5. F. da Silva, S. Linse and B. Jönsson, *J. Phys. Chem. B*, 2005, 109, 2007–2013.
6. T. Kesvatera, B. Jonsson, E. Thulin and S. Linse, *J. Mol. Biol.*, 1996, 259, 828–839.
7. T. Kesvatera, B. Jönsson, E. Thulin and S. Linse, *Proteins: Struct., Funct., Bioinf.*, 1999, 37, 106–115.
8. S. Linse, P. Brodin, C. Johansson, E. Thulin, T. Grundstrom and S. Forsen, *Nature*, 1988, 335, 651–652.
11 S. Lindman, W.-F. Xue, O. Szczepankiewicz, M. C. Bauer, H. Nilsson and S. Linse, *Biophys. J.*, 2006, **90**, 2911–2921.

12 W.-F. Xue, A. L. Hellewell, W. S. Gosal, S. W. Homans, E. W. Hewitt and S. E. Radford, *J. Biol. Chem.*, 2009, **284**, 34272–34282.

13 M. Vendruscolo and C. M. Dobson, *Nature*, 2007, **449**, 555.

14 F. Chiti and C. M. Dobson, *Annu. Rev. Biochem.*, 2006, **75**, 333–366.

15 T. P. J. Knowles, M. Vendruscolo and C. M. Dobson, *Nat. Rev. Mol. Cell Biol.*, 2014, **15**, 384–396.

16 G. Schreiber, G. Haran and H.-X. Zhou, *Chem. Rev.*, 2009, **109**, 839–860.

17 A. K. Buell, P. Hung, X. Salvatella, M. E. Welland, C. M. Dobson and T. P. Knowles, *Biophys. J.*, 2013, **104**, 1116–1126.

18 A. Abelein, A. Graslund and J. Danielsson, *Proc. Natl. Acad. Sci. U. S. A.*, 2015, **112**, 5407–5412.

19 T. P. J. Knowles, C. A. Waudby, G. L. Devlin, S. I. A. Cohen, A. Aguzzi, M. Vendruscolo, E. M. Terentjev, M. E. Welland and C. M. Dobson, *Science*, 2009, **326**, 1533–1537.

20 S. I. A. Cohen, M. Vendruscolo, M. E. Welland, C. M. Dobson, E. M. Terentjev and T. P. J. Knowles, *J. Chem. Phys.*, 2011, **135**, 065105.

21 G. Meisl, J. B. Kirkegaard, P. Arosio, T. T. C. Michaels, M. Vendruscolo, C. M. Dobson, S. Linse and T. P. J. Knowles, *Nat. Protoc.*, 2016, **11**, 252–272.

22 K. Klement, K. Wieligmann, J. Meinhardt, P. Hortschansky, W. Richter and M. Fändrich, *J. Mol. Biol.*, 2007, **373**, 1321–1333.

23 V. Betts, M. A. Leissring, G. Dolios, R. Wang, D. J. Selkoe and D. M. Walsh, *Neurobiol. Dis.*, 2008, **31**, 442–450.

24 M. Lund and B. Jönsson, *Biochemistry*, 2005, **44**, 5722–5727.

25 F. L. B. da Silva, M. Lund, B. Jönsson and T. Akesson, *J. Phys. Chem. B*, 2006, **110**, 4459–4464.

26 F. A. Ferrone, J. Hofrichter and W. A. Eaton, *J. Mol. Biol.*, 1985, **183**, 611–631.

27 S. R. Collins, A. Douglass, R. D. Vale and J. S. Weissman, *PLoS Biol.*, 2004, **2**, e321.

28 W. P. Esler, E. R. Stimson, J. M. Jennings, H. V. Vinters, J. R. Ghilardi, J. P. Lee, P. W. Mantyh and J. E. Maggio, *Biochemistry*, 2000, **39**, 6288–6295.

29 G. Meisl, X. Yang, E. Hellstrand, B. Frohm, J. B. Kirkegaard, S. I. A. Cohen, C. M. Dobson, S. Linse and T. P. J. Knowles, *Proc. Natl. Acad. Sci. U. S. A.*, 2014, **111**, 9384–9389.

30 A. Saric, A. Buell, G. Meisl, T. C. T. Michaels, C. M. Dobson, S. Linse, T. P. J. Knowles and D. Frenkel, *Nat. Phys.*, 2016, **12**, 874–880.

31 S. I. A. Cohen, S. Linse, L. M. Luheshi, E. Hellstrand, D. A. White, L. Rajah, D. E. Otzen, M. Vendruscolo, C. M. Dobson and T. P. J. Knowles, *Proc. Natl. Acad. Sci. U. S. A.*, 2013, **110**, 9758–9763.

32 P. Debye and E. Hückel, *Phys. Z.*, 1923, **24**, 185.

33 J. N. Bronsted and C. E. Teeter, *J. Phys. Chem.*, 1923, **28**, 579–587.

34 N. Bjerrum, *Z. Phys. Chem.*, 1924, **108**, 82.

35 D. DellâÅOrco, W.-F. Xue, E. Thulin and S. Linse, *Biophys. J.*, 2005, **88**, 1991–2002.

36 O. Szczepankiewicz, B. Linse, G. Meisl, E. Thulin, B. Frohm, C. S. Frigerio, M. T. Colvin, A. C. Jacavone, R. G. Griffin, T. Knowles, D. M. Walsh and S. Linse, *J. Am. Chem. Soc.*, 2015, **137**, 14673–14685.

37 G. Meisl, X. Yang, B. Frohm, T. P. J. Knowles and S. Linse, *Sci. Rep.*, 2016, **6**, 18728.

38 B. Bolognesi, S. I. A. Cohen, P. A. Terol, E. K. Esbjärner, S. Giorgetti, M. F. Mossuto, A. Natalelo, A.-C. Brorsson, T. P. J. Knowles, C. M. Dobson and L. M. Luheshi, *ACS Chem. Biol.*, 2014, **9**, 378–382.

39 D. M. Walsh, I. Klyubin, J. V. Fadeeva, W. K. Cullen, R. Anwyl, M. S. Wolfe, M. J. Rowan and D. J. Selkoe, *Nature*, 2002, **416**, 535–539.

40 A. Jan, O. Adolfsson, I. Allaman, A.-L. Buccarello, P. J. Magistretti, A. Pfeifer, A. Muhs and H. A. Lashuel, *J. Biol. Chem.*, 2011, **286**, 8585–8596.

41 D. M. Walsh, E. Thulin, A. M. Minogue, N. Gustavsson, E. Pang, D. B. Teplow and S. Linse, *FEBS J.*, 2009, **276**, 1266–1281.

42 D. J. Wales and J. P. K. Doye, *J. Phys. Chem. A*, 1997, **101**, 5111–5116.